Organovo and Johnson & Johnson Team to Evaluate 3D Bio-printed Tissue Use
It’s only a matter of time before 3D bio-printing really takes off. One of the leaders in the space is Organovo, a company who has already been able to 3D print living liver tissue, and has an ultimate goal of 3D printing a functioning liver for transplantation within a human being.
Before we get there though, there are many useful applications to 3D printed living tissue, which can already be used today. One such application is that of drug discovery testing. Every year billions of dollars are spent performing clinical trials on potential new drugs for the market. Many of these trials involve human beings, oftentimes being put at some risk. Liver toxicity testing, in particular, is usually performed using tissue samples from cadavers, meaning it’s not all that easy to obtain such samples. What 3D bio-printing enables researchers to do, is create live human tissue, which can then be used as a test bed to discover any negative reactions a particular drug may have on that tissue. Once scaled up, such a process could make available as much tissue as is needed for research, as well as tissue of extremely high quality.
Organovo has been leading the way in this space. They have been working for years to perfect the 3D printing techniques required to produce high quality tissue, which is able to stay alive over a long period of time. Today, the company announced an agreement with one of the largest pharmaceutical corporations on the planet, Johnson & Johnson. The actual agreement was signed between Organovo and Janssen Research and Development (JRD), a pharmaceutical company of Johnson & Johnson.
Under this agreement, of which the exact terms have not yet been disclosed, the companies will work together to evaluate the use of 3D bio-printed tissue in a drug discovery setting. Just what kind of tissue, and to what extent the testing will be done, is yet to be seen, however, it certainly bodes well for the progress of 3D bio-printing technology. To have a major, globally recognizable, corporation like Johnson & Johnson on board, could push the adoption of this technology, as well as its progress to a whole to level. It is interesting to note that following the release of an 8K filing disclosing this agreement this morning, shares of Organovo are up over 11%.
What will the implications of this agreement be? Let’s hear your opinions in the Organovo/Johnson & Johnson forum thread on 3DPB.com.
Subscribe to Our Email Newsletter
Stay up-to-date on all the latest news from the 3D printing industry and receive information and offers from third party vendors.
Print Services
Upload your 3D Models and get them printed quickly and efficiently.
You May Also Like
3D Printing Financials: Velo3D Looks to Bounce Back with Defense Deals
Velo3D (OTCQX: VLDX) is working hard to get back on track. The metal 3D printing company brought in $9.3 million in revenue during the first quarter of 2025, slightly below...
Formlabs CEO Says Company Is Caught in US-China Trade Fight
Max Lobovsky, the CEO and co-founder of Formlabs, raised concerns about the challenges his company faces due to ongoing global trade tensions, particularly between the United States and China, in...
University of Illinois Launches AM Research Center with $8M DoD Backing
The Department of Defense (DoD) has awarded $8.15 million to the University of Illinois Urbana-Champaign to support the establishment of an additive manufacturing (AM) research center at the Grainger College...
3D Printing News Briefs, May 3, 2025: Executives, Awards, & a 3D Printing Factory
We’re focusing on additive manufacturing business news today, as both Velo3D and PostProcess Technologies announced changes to their Boards of Directors. Sandvik Metal Powder has a new president, and Klas...